Comparative Pharmacology
Head-to-head clinical analysis: BRINEURA versus LAMZEDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRINEURA versus LAMZEDE.
BRINEURA vs LAMZEDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRINEURA (cerliponase alfa) is a recombinant human tripeptidyl peptidase-1 (TPP1) enzyme that replaces deficient TPP1 in patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease). It hydrolyzes tripeptides from the N-terminus of proteins, reducing accumulation of autofluorescent lipopigments in lysosomes.
Recombinant human iduronate-2-sulfatase (idursulfase) replaces deficient or absent iduronate-2-sulfatase enzyme, which hydrolyzes the 2-sulfate groups from the heparan sulfate and dermatan sulfate GAGs, preventing their accumulation in lysosomes.
400 mg every 2 weeks via intravenous infusion over 1.5 hours.
Intravenous infusion: 1 mg/kg once weekly.
None Documented
None Documented
Terminal half-life is approximately 3 to 4 days (mean 3.5 days) in pediatric patients, supporting weekly intravenous dosing.
Terminal elimination half-life is approximately 100-120 hours. This long half-life supports weekly dosing and maintains therapeutic concentrations throughout the dosing interval.
Primarily catabolized via peptide hydrolysis to small peptides and amino acids; renal excretion of intact enzyme is negligible (<1% of dose).
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Biliary/fecal elimination accounts for >90% of the administered dose.
Category C
Category C
Enzyme Replacement
Enzyme Replacement